Afimkibart para la artritis reumatoide moderada a grave con intolerancia a los inhibidores de TNF/JAK

Afimkibart

Afimkibart

Placebo

Change from Baseline in Disease Activity Score-28 for Rheumatoid Arthritis with C-Reactive Protein (DAS28-CRP)

Percentage of Participants Achieving an American College of Rheumatology 20 Percent (%), 50% or 70% Improvement (ACR20/ACR50/ACR70)

Change from Baseline Disease Activity Score-28 for Rheumatoid Arthritis with Erythrocyte Sedimentation Rate (DAS28-ESR) Score

Change From Baseline in the ACR Core Set - Swollen Joint Count (SJC)

Change From Baseline in the ACR Core Set - Tender Joint Count (TJC)

Change From Baseline in the ACR Core Set - Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)

Change From Baseline in the ACR Core Set - Patient's Global Assessment of Arthritis Pain-Visual Analog Scale (PGA Arthritis Pain-VAS)

Change From Baseline in the ACR Core Set - Patient's Global Assessment of Disease Activity-Visual Analog Scale (PaGADA-VAS)

Change From Baseline in the ACR Core Set - Health Assessment Questionnaire- Disability Index (HAQ-DI)

Change From Baseline in the ACR Core Set - High-sensitivity C-reactive Protein (hsCRP)

Change from Baseline in ACR20, ACR50 and ACR70 Response Rate

Change from Baseline in Simplified Disease Activity Index (SDAI) Score

Change from Baseline in Clinical Disease Activity Index (CDAI) Score

Change from Baseline in Short Form-36 Health Survey (SF-36) Score

Change from Baseline Disease Activity Score-28 for Rheumatoid Arthritis with C-Reactive Protein (DAS28-CRP) Score

Percentage of Participants With Adverse Events (AEs)

Serum Concentration of RO7790121 at Specified Timepoints

Percentage of Participants With Anti-Drug Antibodies